NCT03591380View on ClinicalTrials.gov

CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

May 14, 2019

Primary Completion Date

December 3, 2021

Study Completion Date

December 3, 2021

Conditions
Kidney Transplantation
Interventions
DRUG

Belimumab

Kidney transplant recipients (n=5) will receive standard of care (SOC) therapy consisting of alemtuzumab and steroid induction with mycophenolic acid and tacrolimus maintenance immunosuppression, plus induction and treatment for 6 months with belimumab.

Trial Locations (1)

53792

University of Wisconsin Hospitals and Clinics, Madison

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

American College of Surgeons

OTHER

lead

University of Wisconsin, Madison

OTHER